Who
Lloyd Mitchell Segal
Director
Company insider
Files Form 4 as: Director, Aktis Oncology; President and CEO, Repare Therapeutics; Director, Bausch Health Companies.
In numbers
- Trades disclosed
- 58
- Buys
- 7
- Sells
- 14
- Bought
- $447K
- Sold
- $2.0M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 4 Jan 2010
- Last trade
- 12 Jan 2026
- Last filed
- 12 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Jan 2026filed 12 Jan 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Code C | —19,631 | filing |
| 12 Jan 2026filed 12 Jan 2026 | AKTS Aktis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code C | —50,000 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | AKTS Aktis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code C | —24,687 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | AKTS Aktis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code C | —50,000 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | AKTS Aktis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code C | —24,687 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Code C | —19,631 | filing |
| 12 Mar 2025filed 14 Mar 2025 | Repare Therapeutics | SEC FORM 4 Sold | $24K21,179 at $1.14 | filing |
| 4 Mar 2025filed 6 Mar 2025 | Repare Therapeuticsoption or derivative | SEC FORM 4 Code A | —237,000 at $0.00 | filing |
| 4 Mar 2025filed 6 Mar 2025 | Repare Therapeutics | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 1 Apr 2024filed 1 Apr 2024 | Repare Therapeutics | SEC FORM 4 Sold | $12K2,491 at $4.63 | filing |
| 28 Mar 2024filed 1 Apr 2024 | Repare Therapeutics | SEC FORM 4 Sold | $12K2,650 at $4.62 | filing |
| 27 Mar 2024filed 27 Mar 2024 | Repare Therapeutics | SEC FORM 4 Sold | $12K2,650 at $4.63 | filing |
| 26 Mar 2024filed 27 Mar 2024 | Repare Therapeutics | SEC FORM 4 Sold | $12K2,650 at $4.64 | filing |
| 25 Mar 2024filed 27 Mar 2024 | Repare Therapeutics | SEC FORM 4 Sold | $13K2,650 at $4.79 | filing |
| 1 Mar 2024filed 4 Mar 2024 | Repare Therapeuticsoption or derivative | SEC FORM 4 Code A | —237,000 at $0.00 | filing |
| 1 Mar 2024filed 4 Mar 2024 | Repare Therapeutics | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 30 Jan 2023filed 1 Feb 2023 | Repare Therapeuticsoption or derivative | SEC FORM 4 Code A | —344,200 at $0.00 | filing |
| 30 Jan 2023filed 1 Feb 2023 | Repare Therapeutics | SEC FORM 4 Code A | —78,550 at $0.00 | filing |
| 21 Jan 2022filed 24 Jan 2022 | Repare Therapeuticsoption or derivative | SEC FORM 4 Code M | —300,000 at $0.00 | filing |
| 18 Jan 2022filed 20 Jan 2022 | Repare Therapeuticsoption or derivative | SEC FORM 4 Code M | —300,000 at $0.00 | filing |
News
Contrasting Ocular Therapeutix (NASDAQ:OCUL) and Bausch Health Cos (NYSE:BHC)BHC · dailypolitical.com · 13 Oct 2026Contrasting Bausch Health Cos (NYSE:BHC) and Journey Medical (NASDAQ:DERM)BHC · themarketsdaily.com · 8 Oct 2026
0 headlines in the last 90 days name Lloyd Mitchell Segal; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.